Zymeworks Inc Common Stock

Yahoo Finance • 3 days ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • last month

Zymeworks Q4 Earnings Call Highlights

Zymeworks logo Zymeworks Offers Hope for More than Just Long-Term Investors Zymeworks (NASDAQ:ZYME) executives used the company’s fourth-quarter 2025 results call to highlight updated clinical data for its partnered HER2 antibody zanidat... Full story

Yahoo Finance • last month

Zymeworks Reports FY25 Results, Secures $250 Million Royalty Financing

(RTTNews) - Zymeworks Inc. (ZYME) has reported its fourth-quarter and full-year 2025 financial results while announcing a major $250 million royalty-backed financing agreement with Royalty Pharma, strengthening its balance sheet and extend... Full story

Yahoo Finance • last month

Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma

(RTTNews) - Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company, on Monday entered into a $250 million royalty funding agreement with Royalty Pharma plc (RPRX), a buyer of biopharmaceutical royalties, through a non-recourse r... Full story

Yahoo Finance • last month

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per t... Full story

Yahoo Finance • last month

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per t... Full story

Yahoo Finance • last month

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Zymeworks Inc. Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potent... Full story

Yahoo Finance • last month

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Norwegian Cruise Line Holdings Ltd. (NCLH [https://seekingalpha.com/symbol/NCLH]) * Uniti Group (UNIT [https://seekingalpha.com/symbol/UNIT]) * The Progressive Corporation... Full story

Yahoo Finance • last month

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year

Redmile Group disclosed a significant reduction in its Zymeworks(NASDAQ:ZYME) position in a February 17, 2026, SEC filing, selling an estimated $70.10 million in shares based on quarterly average pricing. What happened According to a Feb... Full story

Yahoo Finance • 3 months ago

Hasbro And 2 Other Stocks That May Be Priced Below Their Estimated Value

As the U.S. stock market navigates a holiday-shortened week, major indices like the Dow Jones, S&P 500, and Nasdaq have seen slight declines following a previous upward trend. In this fluctuating environment, identifying stocks that may be... Full story

Yahoo Finance • 3 months ago

3 Stocks Estimated To Be Priced Below Value In December 2025

As the major stock indexes in the United States continue to log weekly gains, with the S&P 500, Dow Jones Industrial Average, and Nasdaq all showing positive momentum over a holiday-shortened week, investors remain keenly focused on identi... Full story

Yahoo Finance • 3 months ago

Three Companies Estimated To Be Trading Below Their Intrinsic Value

As the U.S. stock market continues to reach new heights, with major indices like the S&P 500 setting all-time records, investors are increasingly looking for opportunities that may be overlooked in this bullish environment. In such a clima... Full story

Yahoo Finance • 3 months ago

3 Stocks Estimated To Be Trading At Discounts Of 23.1% To 41.2%

In a robust market environment where the Dow Jones and S&P 500 have recently set new records, investors are keenly observing opportunities that may be overlooked amid widespread gains. Identifying undervalued stocks can be particularly rew... Full story

Yahoo Finance • 3 months ago

3 Stocks Estimated To Trade At Discounts Of Up To 49.7%

As the U.S. stock market experiences a notable downturn, with major indexes like the S&P 500 and Dow Jones Industrial Average posting consecutive losses amid tech sector retreats and AI bubble concerns, investors are increasingly on the lo... Full story

Yahoo Finance • 4 months ago

Zymeworks Announces Participation in Upcoming Conferences

• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-t... Full story

Yahoo Finance • 4 months ago

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biothe... Full story

Yahoo Finance • 4 months ago

Zymeworks shifts to a royalty-driven business model

[Golden Percentage Symbol] fatido Zymeworks (ZYME [https://seekingalpha.com/symbol/ZYME]) on Tuesday announced plans to focus on a royalty-driven growth model backed by its internal R&D engine and licensing arrangements with companies suc... Full story

Yahoo Finance • 4 months ago

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdatesNews Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on preventive and longevity-focu... Full story

Yahoo Finance • 4 months ago

Zymeworks Appoints Scott Platshon Acting Chief Investment Officer

(RTTNews) - Zymeworks Inc. (ZYME), a Canadian biotechnology company, Tuesday said that it has appointed Scott Platshon as Acting Chief Investment Officer. The company said that Platshon will directly report to Chair and Chief Executive Of... Full story

Yahoo Finance • 4 months ago

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional bioth... Full story